<DOC>
	<DOCNO>NCT00313768</DOCNO>
	<brief_summary>To assess efficacy safety PF-3512676 administer combination paclitaxel , carboplatin bevacizumab first-line treatment patient locally advance metastatic nonsquamous non-small cell lung cancer</brief_summary>
	<brief_title>Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC</brief_title>
	<detailed_description>PF-3512676 dosing stop 21 June 2007 Pfizer decide stop administration PF-3512676 trial combine PF-3512676 cytotoxic chemotherapy . decision make subsequent DSMC recommendation close two phase III randomize trial non-small cell lung cancer also combine PF-3512676 cytotoxic chemotherapy , cite lack efficacy concern primary reason safety issue ( sepsis , thrombocytopenia ) also contribute decision . Subjects allow complete standard care treatment/survival follow-up . Data collection complete 22 May 2008 .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Advanced Stage IIIb pleural effusion Stage IV nonsquamous nonsmall cell lung cancer ECOG Performance Status 01 Measurable disease per RECIST criterion Squamous cell , small cell , carcinoid lung cancer CNS metastasis Preexisting autoimmune antibody mediate disease Prior systemic treatment NSCLC chemo , immunotherapy , biologics , investigation drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>advanced carcinoma , non-small cell lung , Phase II , paclitaxel , Taxol , carboplatin , Paraplatin , bevacizumab , Avastin , PF-3512676 , immunotherapy , immunomodulator</keyword>
</DOC>